Drug Profile
PF 06755347
Alternative Names: GL-2045; PF-06755347Latest Information Update: 24 Jan 2024
Price :
$50
*
At a glance
- Originator Gliknik
- Developer Pfizer
- Class Anti-inflammatories; Biobetters; Neuroprotectants; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic inflammatory demyelinating polyradiculoneuropathy; Idiopathic thrombocytopenic purpura
Most Recent Events
- 24 Jan 2024 Gliknik plans a phase II trial for Chronic inflammatory demyelinating polyradiculoneuropathy
- 03 Feb 2023 Discontinued - Phase-I for Chronic inflammatory demyelinating polyradiculoneuropathy (In volunteers) in New Zealand, United Kingdom (IV)
- 03 Feb 2023 Discontinued - Phase-I for Chronic inflammatory demyelinating polyradiculoneuropathy (In volunteers) in United Kingdom, New Zealand (SC)